Risk factors

Syndax Pharmaceuticals (SNDX) risk factors

Item 1A of every Syndax Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open SNDX in Gloom →
Syndax Pharmaceuticals' chart, financials and news, free in your browser.Open SNDX in Gloom →
  • FY2025 10-K risk factors
    67 risks14 new11 dropped19 reworded

    Syndax transitioned to a commercial-stage company, launching Revuforj in November 2024 and Niktimvo in February 2025.

    Filed Feb 26, 2026
  • FY2024 10-K risk factors
    64 risks

    Syndax relies heavily on the commercial success of newly approved drugs Revuforj and Niktimvo.

    Filed Mar 03, 2025